卡介苗在非霍奇金恶性淋巴瘤免疫治疗中的应用：一项对照试验的初步结果

BCG in the immunotherapy of non-Hodgkin's malignant lymphomas: preliminary results of a controlled trial.

作者信息

Hoerni B, Durand M, de Mascarel A, Richaud P, Hoerni-Simon G, Chauvergne J, Lagarde C

出版信息

Recent Results Cancer Res. 1978;65:160-3. doi: 10.1007/978-3-642-81249-1_19.

Abstract

Thirty-three patients exhibiting non-Hodgkin's malignant lymphoma with one or more criteria of poor prognosis and in whom complete remission had been induced by an association of chemo + radio + chemotherapy were randomized to either receive BCG or no further treatment. The present results indicate that BCG may be useful to maintain remission in about one-third of the patients, but these results are not yet significant.

摘要

33例表现为非霍奇金恶性淋巴瘤且具有一项或多项预后不良标准的患者，他们通过化疗+放疗+化疗联合诱导达到完全缓解，被随机分为两组，一组接受卡介苗治疗，另一组不再接受进一步治疗。目前的结果表明，卡介苗可能有助于约三分之一的患者维持缓解，但这些结果尚不显著。